Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. The company's product candidate portfolio includes evofosfamide to treat pancreatic cancer, glioblastoma, biliary tract cancer, and various solid tumors; and TH-3424 to treat liver cancer, castration-resistant prostate cancer, and T-cell acute lymphoblastic leukemias.